Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 open-label DCP-001 maintenance vaccine study in high-grade serous ovarian cancer
NL-OMON55212Phase 1Active, not recruiting
- Sponsor
- University Medical Center Groningen
- Start
- Jun 2021
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of vididencel in ovarian cancer and High-Grade Serous Ovarian Cancer (HGSOC), sponsored by University Medical Center Groningen. Primary endpoint: Systemic vaccine-specific immune response. Started Jun 2021; status: active, not recruiting.
02
Drugs
vididencel
03
Conditions
ovarian cancerHigh-Grade Serous Ovarian Cancer (HGSOC)
Beyond the preview
Go deeper on NL-OMON55212.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55212.